Superior Glenohumeral Translation in Patients With Degenerative Rotator Cuff Tears (ROTCUFF)

March 2, 2022 updated by: University Hospital, Basel, Switzerland

ROTCUFF - Measuring Load-induced Superior Glenohumeral Translation in Patients With Degenerative Rotator Cuff Tears and Asymptomatic Subjects: 3-dimensional Motion Analysis Versus Single Plane Fluoroscopy

Degenerative partial and complete rupture of the rotator cuff is a common injury among elder patients. However, the clinical manifestation varies largely with some patients having severe pain and limiting range of motion and others having no complaints. The basic functions of the rotator cuff are to facilitate shoulder motion and stabilization and centering of the glenohumeral joint. The objective of this study is to quantify the difference in superior glenohumeral translation in patients with degenerative rotator cuff tear compared to healthy control subjects and to determine the effect of isolated complete supraspinatus tear and combined complete supraspinatus and either partial infraspinatus or partial subscapularis tear.

Study Overview

Detailed Description

The study will examine a cohort of 10 patients with isolated complete supraspinatus muscle tear and 10 patients with complete supraspinatus muscle tear and either partial infraspinatus muscle tear or partial subscapularis muscle tear, and a cohort of 10 age-matched healthy control persons. The participants will be recruited from the Clinic of Orthopaedics and Traumatology at the University Hospital Basel. Inclusion criteria: 45 years < age < 65 years; degenerative complete supraspinatus muscle tear or complete supraspinatus muscle tear and either partial infraspinatus muscle tear or partial subscapularis muscle tear; unilateral rotator cuff tear. Exclusion criteria: traumatic tendon ruptures; prior treatment of the ipsilateral upper extremity; clinical history of the contralateral glenohumeral joint; no complete supraspinatus muscle tear; tears in more than two rotator cuff muscles; neuromuscular disorders affecting upper limb movement; additional pathologies that influence the mobility of the shoulder joint; inability to provide informed consent.

Patients will complete the health questionnaire and reflective markers and electromyographic sensors will be placed on anatomical landmarks and shoulder muscles, respectively, before loaded and unloaded abduction and flexion arm movements will be performed. Centre of rotation of both shoulders will be calculated to determine glenohumeral translation. This parameter will be compared between patient groups and control subjects using linear mixed models with group membership and load as fixed factor and subject as random factor. The critical shoulder angle will be included as covariate into the model to detect a potential modulating role of this factor on glenohumeral translation.

Study Type

Observational

Enrollment (Actual)

21

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Basel Stadt
      • Basel, Basel Stadt, Switzerland, 4031
        • University Hospital Basel

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

45 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

  • 10 patients with isolated complete supraspinatus muscle tear
  • 10 patients with complete supraspinatus muscle tear and either partial infraspinatus muscle tear or partial subscapularis muscle tear
  • 10 healthy control subjects

Description

Inclusion criteria patients

  • 45 years ≤ age ≤ 65 years
  • Degenerative complete supraspinatus muscle tear or complete supraspinatus muscle tear and either partial infraspinatus muscle tear or partial subscapularis muscle tear
  • Unilateral rotator cuff tear

Exclusion criteria patients

  • Traumatic tendon ruptures
  • Incomplete supraspinatus muscle tear
  • Tears in more than two rotator cuff muscles
  • Prior conservative treatment or surgery of the ipsilateral upper extremity
  • Clinical history of the contralateral glenohumeral joint
  • Range of motion < 90° in abduction and flexion
  • Neuromuscular disorders affecting upper limb movement
  • Additional pathologies that influence the mobility of the shoulder joints
  • Inability to provide informed consent

Inclusion criteria healthy control subjects

• 45 years ≤ age ≤ 65 years

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Retrospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Control group
age and sex matched healthy control persons
amount of glenohumeral translation under load
isolated tear
patients with isolated complete supraspinatus muscle tear
amount of glenohumeral translation under load
combined tear
patients with complete supraspinatus muscle tear and either partial infraspinatus muscle tear or partial subscapularis muscle tear
amount of glenohumeral translation under load

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Glenohumeral translation
Time Frame: Baseline
Amount of glenohumeral translation under load
Baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Disabilities of arm, shoulder and Hand (DASH)
Time Frame: Baseline
assessed using the Quick DASH (0 - no problems, 100 - extreme problems)
Baseline
Shoulder function
Time Frame: Baseline
assessed using the Constant Shoulder Score (0 - no problems, >30 extreme problems)
Baseline
Shoulder pain
Time Frame: Baseline
assessed using a 15 cm visual analogue scale converted to 0 to 100 scale (0 - no pain; 100 - worst pain imaginable)
Baseline
Critical shoulder angle (CSA)
Time Frame: Baseline
measured on frontal plane radiographs in neutral arm position available from the clinical consultation. The CSA is the angle between the line connecting the superior with the inferior border of the glenoid fossa and the line connecting the inferior border of the glenoid fossa with the most inferolateral point of the acromion
Baseline
Muscle activity
Time Frame: Baseline
root mean square of the electromyography (EMG) signal during the arm movements calculated and normalised to the maximal obtained signal intensity
Baseline
Glenohumeral translation from fluoroscopy
Time Frame: Baseline
the perpendicular distance of the centre of the glenohumeral joint and the x-axis of the scapula coordinate system will be measured. Glenohumeral translation will be defined as the difference in this distance between the abducted arm positions and the resting arm position
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Annegret Mündermann, PhD, University Hospital, Basel, Switzerland

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 4, 2018

Primary Completion (Actual)

February 22, 2019

Study Completion (Actual)

September 30, 2020

Study Registration Dates

First Submitted

October 22, 2018

First Submitted That Met QC Criteria

October 22, 2018

First Posted (Actual)

October 24, 2018

Study Record Updates

Last Update Posted (Actual)

March 3, 2022

Last Update Submitted That Met QC Criteria

March 2, 2022

Last Verified

March 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • EKNZ 2018-01692

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Rotator Cuff Tear or Rupture, Not Specified as Traumatic

Clinical Trials on Glenohumeral translation assessment

3
Subscribe